BioWorld

Nov. 16, 2009

Ziopharm's Bet: Cancer Pills Will Beat I.V.; Off-On Method Intrigues

"Ruthlessly efficient" is how Jonathan Lewis, CEO and chief medical officer of Ziopharm Oncology Inc., last week described his firm's approach to research and financial management. Read More

Money Raised Year to Date

No Public Funds or Partners: Can Istodax Be New Approval Model?

Enzon's Specialty-Biz Offload Leaves Convertible Overhang

Money Raised By Biotech in 2009

Week in Review

Word on the Street

Week in Washington

FDA Approvals for October

Phase I Clinical Trials Update: October 2009

Phase II Clinical Trials Update: October 2009

Pivotal/Phase III Clinical Trials Update: October 2009

American College of Rheumatology

American Association for the Study of Liver Disease

Non-U.S. Clinical Trials And Regulatory Actions: October 2009

FDA Submissions, Approvals And Other Actions: October 2009

Stock Gainers and Losers For The Week

BioWorld Stock Report For Public Biotechnology Companies

Today's news in brief

BioWorld

BioWorld briefs for June 17, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 16, 2026

For clonal hematopoiesis, epigenetics can be in driver’s seat

BioWorld Science

Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...

Illustration of amyloid plaques in Alzheimer's disease

Elixiron’s enrupatinib shows upbeat interim phase II AD results

BioWorld

Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...

Gene replacement rescues autism-related phenotypes in mice

BioWorld Science

Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...